{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:40:59Z","timestamp":1769110859328,"version":"3.49.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Mayo Clinic Center for Clinical and Translational Science (CCaTS) Benefactor Career Development Award"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["CSDG-23-1020347-01-IBCD"],"award-info":[{"award-number":["CSDG-23-1020347-01-IBCD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00757-y","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:32:04Z","timestamp":1758882724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance"],"prefix":"10.1007","volume":"20","author":[{"given":"Ali Khalid A","family":"Alsugair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"1","key":"757_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41375-018-0203-0","volume":"33","author":"S Niyongere","year":"2019","unstructured":"Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019;33(1):205\u201316.","journal-title":"Leukemia"},{"issue":"20","key":"757_CR2","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/bloodadvances.2019000585","volume":"3","author":"A Franzini","year":"2019","unstructured":"Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, et al. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv. 2019;3(20):2949\u201361.","journal-title":"Blood Adv"},{"issue":"6","key":"757_CR3","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1080\/10428194.2016.1243681","volume":"58","author":"MF Zahid","year":"2017","unstructured":"Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, et al. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma. 2017;58(6):1488\u201393.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"757_CR4","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1182\/bloodadvances.2020002415","volume":"4","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, et al. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020;4(21):5425\u201330.","journal-title":"Blood Adv"},{"issue":"3","key":"757_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41590-025-02096-9","volume":"26","author":"Z Ciantra","year":"2025","unstructured":"Ciantra Z, Paraskevopoulou V, Aifantis I. The rewired immune microenvironment in leukemia. Nat Immunol. 2025;26(3):351\u201365.","journal-title":"Nat Immunol"},{"issue":"6","key":"757_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","volume":"4","author":"A Nelde","year":"2023","unstructured":"Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, et al. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. Blood Cancer Discov. 2023;4(6):468\u201389.","journal-title":"Blood Cancer Discov"},{"key":"757_CR7","doi-asserted-by":"publisher","unstructured":"Mangaonkar AA, Patnaik MM. Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation. Leuk Lymphoma. 2022. https:\/\/doi.org\/10.1080\/10428194.2022.2056175.","DOI":"10.1080\/10428194.2022.2056175"},{"issue":"11","key":"757_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ajh.21848","volume":"85","author":"KN Naresh","year":"2010","unstructured":"Naresh KN, Pavlu J. Plasmacytoid dendritic cell nodules in bone marrow biopsies of chronic myelomonocytic leukemia. Am J Hematol. 2010;85(11):893.","journal-title":"Am J Hematol"},{"issue":"10","key":"757_CR9","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","volume":"33","author":"N Lucas","year":"2019","unstructured":"Lucas N, Duchmann M, Rameau P, No\u00ebl F, Michea P, Saada V, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019;33(10):2466\u201380.","journal-title":"Leukemia"},{"key":"757_CR10","doi-asserted-by":"publisher","unstructured":"Mangaonkar AA, Patnaik MM. Advances in chronic myelomonocytic leukemia and future prospects: lessons learned from precision genomics. Adv Cell Gene Ther. 2019. https:\/\/doi.org\/10.1002\/acg2.48.","DOI":"10.1002\/acg2.48"},{"issue":"6","key":"757_CR11","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99(6):1142\u201365.","journal-title":"Am J Hematol"},{"issue":"12","key":"757_CR12","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/2159-8290.CD-22-0086","volume":"12","author":"JM SanMiguel","year":"2022","unstructured":"SanMiguel JM, Eudy E, Loberg MA, Young KA, Mistry JJ, Mujica KD, et al. Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 2022;12(12):2763\u201373.","journal-title":"Cancer Discov"},{"issue":"7512","key":"757_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz L, S\u00e1nchez-Aguilera A, Mart\u00edn-P\u00e9rez D, Isern J, Langa X, Tzankov A, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014;512(7512):78\u201381.","journal-title":"Nature"},{"issue":"2","key":"757_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"key":"757_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2017.11.002","volume":"59","author":"SO Abegunde","year":"2018","unstructured":"Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment containing TNF\u03b1 favors Tet2-mutant clonal hematopoiesis. Exp Hematol. 2018;59:60\u20135.","journal-title":"Exp Hematol"},{"issue":"1","key":"757_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41421-017-0004-z","volume":"4","author":"P Zhang","year":"2018","unstructured":"Zhang P, Chen Z, Li R, Guo Y, Shi H, Bai J, et al. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates. Cell Discov. 2018;4(1):4.","journal-title":"Cell Discov"},{"issue":"7569","key":"757_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525(7569):389\u201393.","journal-title":"Nature"},{"issue":"16","key":"757_CR18","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa2413361","volume":"392","author":"O Pich","year":"2025","unstructured":"Pich O, Bernard E, Zagorulya M, Rowan A, Pospori C, Slama R, et al. Tumor-infiltrating clonal hematopoiesis. N Engl J Med. 2025;392(16):1594\u2013608.","journal-title":"N Engl J Med"},{"issue":"14","key":"757_CR19","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1016\/j.cell.2024.05.003","volume":"187","author":"H Wang","year":"2024","unstructured":"Wang H, Divaris K, Pan B, Li X, Lim JH, Saha G, et al. Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss. Cell. 2024;187(14):3690\u2013e71119.","journal-title":"Cell"},{"issue":"16","key":"757_CR20","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1182\/bloodadvances.2018024729","volume":"3","author":"EK Cook","year":"2019","unstructured":"Cook EK, Izukawa T, Young S, Rosen G, Jamali M, Zhang L, et al. Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Adv. 2019;3(16):2482\u20136.","journal-title":"Blood Adv"},{"issue":"3","key":"757_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41375-024-02511-4","volume":"39","author":"HM Addinsell","year":"2025","unstructured":"Addinsell HM, Cant R, Hull NJ, Wang YH, Somervaille TCP, Wiseman DH, et al. Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization. Leukemia. 2025;39(3):770\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"757_CR22","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","volume":"34","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo clinic-Moffitt cancer center study of 135 consecutive patients. Leukemia. 2020;34(2):656\u201361.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"757_CR23","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/blood-2023-186856","volume":"142","author":"AA Mangaonkar","year":"2023","unstructured":"Mangaonkar AA, Lasho TL, Boysen J, Finke CM, Fernandez JA, Villasboas JC, et al. Cellular interactions within clonal dendritic cell aggregates drive immune tolerance in chronic myelomonocytic leukemia bone marrow microenvironment. Blood. 2023;142(Supplement 1):4077.","journal-title":"Blood"},{"key":"757_CR24","doi-asserted-by":"crossref","unstructured":"You X, Liu F, Binder M, Vedder A, Lasho TL, Wen Z et al. Asxl1loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. Blood. 2021.","DOI":"10.1182\/blood.2021012519"},{"key":"757_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2015.00068","volume":"3","author":"JR Kemp","year":"2015","unstructured":"Kemp JR, Longworth MS. Crossing the LINE toward genomic instability: LINE-1 retrotransposition in cancer. Front Chem. 2015;3:68.","journal-title":"Front Chem"},{"issue":"3","key":"757_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2159256X.2015.1037416","volume":"5","author":"VP Belancio","year":"2015","unstructured":"Belancio VP. Line-1 activity as molecular basis for genomic instability associated with light exposure at night. Mob Genet Elem. 2015;5(3):1\u20135.","journal-title":"Mob Genet Elem"},{"issue":"7","key":"757_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00262-011-1183-3","volume":"61","author":"CS Mullins","year":"2012","unstructured":"Mullins CS, Linnebacher M. Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunol Immunother. 2012;61(7):1093\u2013100.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"757_CR28","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.1038\/s41598-017-07356-9","volume":"7","author":"AR Colombo","year":"2017","unstructured":"Colombo AR, Zubair A, Thiagarajan D, Nuzhdin S, Triche TJ, Ramsingh G. Suppression of transposable elements in leukemic stem cells. Sci Rep. 2017;7(1):7029.","journal-title":"Sci Rep"},{"issue":"1","key":"757_CR29","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s42003-024-07214-1","volume":"7","author":"D Hidaoui","year":"2024","unstructured":"Hidaoui D, Porquet A, Chelbi R, Bohm M, Polyzou A, Alcazer V, et al. Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathways. Commun Biol. 2024;7(1):1555.","journal-title":"Commun Biol"},{"issue":"10","key":"757_CR30","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.stem.2021.04.030","volume":"28","author":"A Avgustinova","year":"2021","unstructured":"Avgustinova A, Laudanna C, Pascual-Garc\u00eda M, Rovira Q, Djurec M, Castellanos A, et al. Repression of endogenous retroviruses prevents antiviral immune response and is required for mammary gland development. Cell Stem Cell. 2021;28(10):1790\u2013. \u2013\u2009804.e8.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"757_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf8627","volume":"8","author":"AM Hansen","year":"2022","unstructured":"Hansen AM, Ge Y, Schuster MB, Pundhir S, Jakobsen JS, Kalvisa A, et al. H3k9 dimethylation safeguards cancer cells against activation of the interferon pathway. Sci Adv. 2022;8(11):eabf8627.","journal-title":"Sci Adv"},{"issue":"9","key":"757_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0145-2126(01)00014-5","volume":"25","author":"T N\u00f6sslinger","year":"2001","unstructured":"N\u00f6sslinger T, Reisner R, Gr\u00fcner H, T\u00fcchler H, Nowotny H, Pittermann E, et al. Dysplastic versus proliferative CMML \u2013 a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001;25(9):741\u20137.","journal-title":"Leuk Res"},{"issue":"22","key":"757_CR33","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood.V128.22.1987.1987","volume":"128","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke C, Howard MT, Hanson CA, Ketterling RP, et al. Proliferative versus dysplastic chronic myelomonocytic leukemia: molecular and prognostic correlates. Blood. 2016;128(22):1987.","journal-title":"Blood"},{"issue":"4","key":"757_CR34","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","volume":"87","author":"JM Bennett","year":"1994","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French - American - British cooperative leukaemia group. Br J Haematol. 1994;87(4):746\u201354.","journal-title":"Br J Haematol"},{"issue":"22","key":"757_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/blood.V128.22.110.110","volume":"128","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Barraco D, Lasho TL, Tolosa E, Almada LL, Davila JI, et al. Gene expression profiling identifies distinct signatures for dysplastic and proliferative chronic myelomonocytic leukemia. Blood. 2016;128(22):110.","journal-title":"Blood"},{"issue":"Supplement1","key":"757_CR36","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1182\/blood-2019-123877","volume":"134","author":"RM Carr","year":"2019","unstructured":"Carr RM, Lasho T, Marks D, Tolosa E, Almada LL, Alver B, et al. Clinical categorization of chronic myelomonocytic leukemia into proliferative and dysplastic subtypes correlates with distinct genomic, transcriptomic and epigenomic signatures. Blood. 2019;134(Supplement1):1710.","journal-title":"Blood"},{"issue":"4","key":"757_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25(4):603\u201311.","journal-title":"Nat Med"},{"issue":"1","key":"757_CR38","doi-asserted-by":"publisher","first-page":"12892","DOI":"10.1038\/s41598-017-12940-0","volume":"7","author":"A Mangaonkar","year":"2017","unstructured":"Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, et al. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. Sci Rep. 2017;7(1):12892.","journal-title":"Sci Rep"},{"issue":"10","key":"757_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri1457","volume":"4","author":"AL Mellor","year":"2004","unstructured":"Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"757_CR40","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.2174\/092986711795656045","volume":"18","author":"DH Munn","year":"2011","unstructured":"Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem. 2011;18(15):2240\u20136.","journal-title":"Curr Med Chem"},{"issue":"5","key":"757_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147\u201354.","journal-title":"J Clin Invest"},{"issue":"5","key":"757_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122(5):749\u201358.","journal-title":"Blood"},{"issue":"5","key":"757_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.12774","volume":"165","author":"N Dulphy","year":"2014","unstructured":"Dulphy N, Henry G, Hemon P, Khaznadar Z, Dombret H, Boissel N, et al. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br J Haematol. 2014;165(5):722\u20135.","journal-title":"Br J Haematol"},{"issue":"15","key":"757_CR44","doi-asserted-by":"publisher","first-page":"eadf8522","DOI":"10.1126\/sciadv.adf8522","volume":"9","author":"I Weinh\u00e4user","year":"2023","unstructured":"Weinh\u00e4user I, Pereira-Martins DA, Almeida LY, Hilberink JR, Silveira DRA, Quek L, et al. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism. Sci Adv. 2023;9(15):eadf8522.","journal-title":"Sci Adv"},{"issue":"7","key":"757_CR45","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Y Kong","year":"2015","unstructured":"Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015;5(7):e330.","journal-title":"Blood Cancer J"},{"issue":"9","key":"757_CR46","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470\u201381.","journal-title":"Cancer"},{"issue":"7","key":"757_CR47","doi-asserted-by":"publisher","first-page":"e0131761","DOI":"10.1371\/journal.pone.0131761","volume":"10","author":"T Tian","year":"2015","unstructured":"Tian T, Yu S, Liu L, Xue F, Yuan C, Wang M, et al. The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations. PLoS ONE. 2015;10(7):e0131761.","journal-title":"PLoS ONE"},{"issue":"1","key":"757_CR48","doi-asserted-by":"publisher","first-page":"17179","DOI":"10.1038\/s41598-025-01711-x","volume":"15","author":"Y Gu","year":"2025","unstructured":"Gu Y, Xia J, Guo Y, Tao L, Zhang G, Xu J. Leukemia cells remodel bone marrow stromal cells to generate a protumoral microenvironment via the S100A8-NOX2-ROS signaling pathway. Sci Rep. 2025;15(1):17179.","journal-title":"Sci Rep"},{"issue":"1","key":"757_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115151","volume":"44","author":"LE Lisi-Vega","year":"2025","unstructured":"Lisi-Vega LE, Pievani A, Garc\u00eda-Fern\u00e1ndez M, Forte D, Williams TL, Serafini M, et al. Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia. Cell Rep. 2025;44(1):115151.","journal-title":"Cell Rep"},{"issue":"1","key":"757_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo R, L\u00fc M, Cao F, Wu G, Gao F, Pang H, et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res. 2021;9(1):15.","journal-title":"Biomark Res"},{"issue":"6","key":"757_CR51","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","volume":"26","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, et al. The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transplant. 2020;26(6):1137\u201343.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"757_CR52","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280\u20138.","journal-title":"Leukemia"},{"key":"757_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.647713","volume":"9","author":"X Li","year":"2021","unstructured":"Li X, Dong L, Liu J, Wang C, Zhang Y, Mei Q, et al. Low-dose decitabine augments the activation and anti-tumor immune response of IFN-\u03b3(+) CD4(+) T cells through enhancing I\u03baB\u03b1 degradation and NF-\u03baB activation. Front Cell Dev Biol. 2021;9:647713.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"757_CR54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2020008477","volume":"138","author":"P Han","year":"2021","unstructured":"Han P, Hou Y, Zhao Y, Liu Y, Yu T, Sun Y, et al. Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood. 2021;138(8):674\u201388.","journal-title":"Blood"},{"issue":"12","key":"757_CR55","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/ijc.25635","volume":"128","author":"BJ Schmiedel","year":"2011","unstructured":"Schmiedel BJ, Ar\u00e9lin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer. 2011;128(12):2911\u201322.","journal-title":"Int J Cancer"},{"issue":"10","key":"757_CR56","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.22.00437","volume":"41","author":"R Itzykson","year":"2023","unstructured":"Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, et al. Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol. 2023;41(10):1888\u201397.","journal-title":"J Clin Oncol"},{"issue":"4","key":"757_CR57","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1083\/jcb.127.4.1121","volume":"127","author":"SK Gupta","year":"1994","unstructured":"Gupta SK, Singh JP. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol. 1994;127(4):1121\u20137.","journal-title":"J Cell Biol"},{"issue":"11","key":"757_CR58","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nm.3707","volume":"20","author":"I Bruns","year":"2014","unstructured":"Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315\u201320.","journal-title":"Nat Med"},{"issue":"5","key":"757_CR59","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1172\/JCI78752","volume":"125","author":"K Meldi","year":"2015","unstructured":"Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125(5):1857\u201372.","journal-title":"J Clin Invest"},{"issue":"2","key":"757_CR60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/leu.2017.186","volume":"32","author":"V Santini","year":"2018","unstructured":"Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413\u20138.","journal-title":"Leukemia"},{"issue":"22","key":"757_CR61","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1158\/1078-0432.CCR-21-0935","volume":"27","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Newman H, Dezern AE, Steensma DP, Niyongere S, Roboz GJ, et al. Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia. Clin Cancer Res. 2021;27(22):6095\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"757_CR62","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2022-170144","volume":"140","author":"E Padron","year":"2022","unstructured":"Padron E, Tinsley-Vance SM, DeZern AE, Carraway HE, Luskin MR, Roboz GJ, et al. Efficacy and safety of ruxolitinib for treatment of symptomatic chronic myelomonocytic leukemia (CMML): results of a multicenter phase II clinical trial. Blood. 2022;140(Supplement 1):1101\u20133.","journal-title":"Blood"},{"issue":"2","key":"757_CR63","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","volume":"93","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol. 2018;93(2):277\u201385.","journal-title":"Am J Hematol"},{"issue":"5","key":"757_CR64","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/10428194.2017.1369070","volume":"59","author":"S Burgstaller","year":"2018","unstructured":"Burgstaller S, Stauder R, Kuehr T, Lang A, Machherndl-Spandl S, Mayrbaeurl B, et al. A phase I study of Lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. Leuk Lymphoma. 2018;59(5):1121\u20136.","journal-title":"Leuk Lymphoma"},{"key":"757_CR65","doi-asserted-by":"publisher","unstructured":"Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, et al. Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1\/2 study. Blood Neoplasia. 2025. https:\/\/doi.org\/10.1016\/j.bneo.2025.100115.","DOI":"10.1016\/j.bneo.2025.100115"},{"issue":"7","key":"757_CR66","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood.2019004352","volume":"136","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, et al. Phase 1 study of lenzilumab, a recombinant anti\u2013human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020;136(7):909\u201313.","journal-title":"Blood"},{"issue":"Supplement 1","key":"757_CR67","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2023-185259","volume":"142","author":"JJ Rodriguez Sevilla","year":"2023","unstructured":"Rodriguez Sevilla JJ, Adema V, Chien KS, Ganan-Gomez I, Montalban-Bravo G, Urrutia S, et al. A phase 2 study of Canakinumab in patients with lower-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood. 2023;142(Supplement 1):1866.","journal-title":"Blood"},{"issue":"2","key":"757_CR68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ajh.27161","volume":"99","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al. Phase Ib study of Sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024;99(2):E32-6.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"757_CR69","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood-2024-206538","volume":"144","author":"GN Mannis","year":"2024","unstructured":"Mannis GN, Aribi A, Dunavin N, Carraway HE, Saultz JN, Roboz GJ, et al. IO-202, a novel anti-LILRB4 antibody, with Azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1b expansion cohort results. Blood. 2024;144(Supplement 1):1008.","journal-title":"Blood"},{"issue":"Supplement 1","key":"757_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2024-198326","volume":"144","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, Abaza Y, Greenberg PL, Haque T, Vel\u00e1zquez Kennedy K, Della Porta MG, et al. Preliminary safety and biomarker results of the NLRP3 inflammasome inhibitor DFV890 in adult patients with myeloid diseases: a phase 1b study. Blood. 2024;144(Supplement 1):353.","journal-title":"Blood"},{"issue":"Supplement 1","key":"757_CR71","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.1182\/blood-2022-156786","volume":"140","author":"I Pawlitzky","year":"2022","unstructured":"Pawlitzky I, Siitonen T, Daver N, Jalkanen J, Aako S, Fj\u00e4llskog M-L, et al. Trial in progress: a phase I\/II study to assess safety, tolerability and preliminary efficacy of Bexmarilimab in combination with standard of care in patients with hematological malignancies (BEXMAB). Blood. 2022;140(Supplement 1):11751\u20132.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00757-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00757-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00757-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:32Z","timestamp":1769051012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00757-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00757-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11"}}